PharmaMar Group Shows Steady Growth in H1 2024
Company Announcements

PharmaMar Group Shows Steady Growth in H1 2024

Pharma Mar SA (ES:PHM) has released an update.

PharmaMar Group reports a slight 1% increase in total revenues to 80.8 million euros for the first half of 2024, buoyed by royalty income growth of 16% and a significant 85% jump in raw material sales. Despite a dip in oncology sales, the company’s net profit stands at 3.5 million euros, with research and development investments up 10%. The financial health of the company is further indicated by a 9% reduction in debt and a strong cash position.

For further insights into ES:PHM stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Spain Auto-Generated NewsdeskPharma Mar Hits $10 Million Milestone with Janssen
TipRanks Auto-Generated NewsdeskPharma Mar SA Reports Strong Revenue Growth in 2024
TipRanks Spain Auto-Generated NewsdeskPharma Mar S.A. Announces Strategic Share Capital Reduction
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App